MorphoSys is focused on creating significant value for all of its stakeholders through a strategy that balances short- and long-term growth potential. By applying its proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies. The company has established successful and lasting partnerships with industry-leading companies from the pharmaceutical and biotechnology sectors. Our product pipeline, one of the broadest in the antibody industry, proves the sustainable quality of MorphoSys’s work. Through specific in-licensing and co-development activities, the company is adding higher-value programs to the pipeline at a significant rate. Our comprehensive partnering strategy is an important feature of our business model and a vital source of MorphoSys’s financial strength.
In 2018, MorphoSys US Inc. (MorphoSys US) was formed as a wholly owned MorphoSys subsidiary. MorphoSys US was established with the goal to build commercial capabilities in this important market.